<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03216499</url>
  </required_header>
  <id_info>
    <org_study_id>ABTC 1602</org_study_id>
    <secondary_id>IRB00132128</secondary_id>
    <secondary_id>UM1CA137443</secondary_id>
    <nct_id>NCT03216499</nct_id>
  </id_info>
  <brief_title>HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma</brief_title>
  <acronym>PT2385</acronym>
  <official_title>Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peloton Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well HIF-2 alpha inhibitor PT2385 works in treating patients&#xD;
      with recurrent glioblastoma. HIF-2 alpha inhibitor PT2385 may stop the growth of tumor cells&#xD;
      by blocking some of the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the efficacy of hypoxia inducible factor (HIF)-2 alpha inhibitor PT2385&#xD;
      (PT2385) as measured by radiographic response rate (by Response Assessment in Neuro-Oncology,&#xD;
      RANO, criteria) in patients with recurrent glioblastoma.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the efficacy of PT2385 as measured by progression free and overall survival in&#xD;
      patients with recurrent glioblastoma.&#xD;
&#xD;
      II. To determine the safety of oral PT2385 in patients with recurrent glioblastoma.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To describe the pharmacokinetic and pharmacodynamic properties of PT2385 in patients with&#xD;
      recurrent glioblastoma.&#xD;
&#xD;
      II. To describe baseline intratumoral hypoxia using novel, advanced magnetic resonance&#xD;
      (MR)-based neuroimaging sequences in patients with recurrent glioblastoma.&#xD;
&#xD;
      III. To explore genetic polymorphisms involved in the metabolism of PT2385.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive HIF-2 alpha inhibitor PT2385 orally (PO) twice daily (BID) on days 1-28.&#xD;
      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 2 months for 2 years and&#xD;
      every 6 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2017</start_date>
  <completion_date type="Actual">June 5, 2020</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Radiographic Response as Assessed by the RANO Criteria</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Tumor radiographic response assessed by Response Assessment in Neuro-Oncology (RANO) criteria.&#xD;
Complete Response (CR) = no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable or reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable or improved clinical status&#xD;
Partial Response (PR) = ≥50% change in size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status&#xD;
Stable Disease (SD) = &lt;50% reduction to &lt;25% increase size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status&#xD;
Progressive Disease (PD) = ≥25% increase size of T1-Gd+ disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Assessed up to 2 years</time_frame>
    <description>PFS (in months) will be estimated using Kaplan-Meier method along with 95% confidence interval. Definition of PFS is date treatment started to the date of progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the date of treatment start to the date of death occurrence/or censored at the time of last known alive, assessed up to 2 years</time_frame>
    <description>Overall survival (in months) will be estimated using Kaplan-Meier method along with 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 3 and Grade 4 Adverse Events</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Number of participants experiencing grade 3 and grade 4 adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetics (Cmin) for PT2385</measure>
    <time_frame>Day 15 cycle 1</time_frame>
    <description>Minimum concentration (Cmin) on Day 15 of cycle 1.&#xD;
Cycle 1, Week 1, Day 1, Pre-dose 1: within 15 minutes prior to dose&#xD;
Cycle 1, Week 1, Day 1, 6 Hours Post-dose 1: 6 hours +/- 15 minutes post-dose&#xD;
Cycle 1, Week 3, Day 15, Pre-dose 1: within 30 minutes prior to dose</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetics for PT2385 Drug Exposure</measure>
    <time_frame>Day 15 cycle 1</time_frame>
    <description>Drug exposure levels in 3 groups: Cmin &gt;1000ng/mL; Cmin: 300-1000 ng/mL and Cmin &lt;300ng/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>Determine Association Between Baseline Tumor Acidity and PT2385 (Imaging)</measure>
    <time_frame>At baseline</time_frame>
    <description>Baseline Tumor acidity was measured using pH-weighted amine chemical exchange saturation transfer (CEST) MRI contrast on the Magnetic Resonance Imaging R^2 = &quot;reversible transverse relaxation rate&quot; (and is proportional to oxygen extraction and thus hypoxia).&#xD;
MTR = MTRasym &quot;the asymmetry in the magnetization transfer ratio at 3ppm from water&quot; (and it is a surrogate of tumor acidity (MTR) pH quantitative measure of the acidity or basicity (pH) of aqueous or other liquid solutions. Lower pH values correspond to solutions which are more acidic in nature, while higher values correspond to solutions which are more basic or alkaline.&#xD;
Exp = exposure Acid = Acidity Perit Tiss = Peritumoral Tissue Enh Tum = Enhancing Tumor DurTx = Duration treatment</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Treatment (HIF-2 alpha inhibitor PT2385)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive HIF-2 alpha inhibitor PT2385 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Pharmacological Study&#xD;
Laboratory Biomarker Analysis&#xD;
Pharmacogenomic Study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIF-2alpha Inhibitor PT2385</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (HIF-2 alpha inhibitor PT2385)</arm_group_label>
    <other_name>HIF-2alpha Inhibitor PT2385, PT2385</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (HIF-2 alpha inhibitor PT2385)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (HIF-2 alpha inhibitor PT2385)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacogenomic Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (HIF-2 alpha inhibitor PT2385)</arm_group_label>
    <other_name>PHARMACOGENOMIC, Pharmacogenomic Study</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Patients must have histologically confirmed glioblastoma that is progressive or&#xD;
             recurrent following radiation therapy and temozolomide according to the Response&#xD;
             Assessment in Neuro-Oncology (RANO) criteria with:&#xD;
&#xD;
               -  New contrast-enhancing lesion outside of radiation field on decreasing, stable,&#xD;
                  or increasing doses of corticosteroids&#xD;
&#xD;
               -  Increase by &gt;= 25% in the sum of the products of perpendicular diameters between&#xD;
                  the postradiotherapy scan with the smallest tumor measurement and a scan at least&#xD;
                  12 weeks from completion of radiation therapy (RT) + temozolomide (TMZ), on&#xD;
                  stable or increasing doses of corticosteroids&#xD;
&#xD;
                  ** Note: clinical deterioration not attributable to concurrent medication or&#xD;
                  comorbid conditions is sufficient to declare progression on current treatment but&#xD;
                  not for entry onto a clinical trial for recurrence&#xD;
&#xD;
                    -  Tumor O(6)-methylguanine-DNA-methyltransferase (MGMT) methylation status&#xD;
                       must be available; results of routinely used methods for MGMT methylation&#xD;
                       testing (e.g. mutagenically separated polymerase chain reaction, (MSPCR), or&#xD;
                       quantitative polymerase chain reaction (PCR)) are acceptable&#xD;
&#xD;
                    -  Patients must have a tumor tissue form indicating availability of archived&#xD;
                       tissue from a previous surgery for glioblastoma, completed and signed by a&#xD;
                       pathologist&#xD;
&#xD;
                    -  Patients must have measurable (defined by at least 1 cm x 1 cm)&#xD;
                       contrast-enhancing disease by magnetic resonance imaging (MRI) imaging&#xD;
                       within 21 days of starting treatment&#xD;
&#xD;
                    -  Patients must be able to undergo MRI of the brain with gadolinium; patients&#xD;
                       must be maintained on a stable or decreasing dose of corticosteroid regimen&#xD;
                       (no increase for 5 days) prior to this baseline MRI&#xD;
&#xD;
                    -  Patients must be in first recurrence of glioblastoma following radiation&#xD;
                       therapy and temozolomide&#xD;
&#xD;
                    -  Patients must have recovered from severe toxicity of prior therapy; the&#xD;
                       following intervals from previous treatments are required to be eligible:&#xD;
&#xD;
               -  12 weeks from the completion of radiation&#xD;
&#xD;
               -  6 weeks from a nitrosourea chemotherapy&#xD;
&#xD;
               -  3 weeks from a non-nitrosourea chemotherapy&#xD;
&#xD;
               -  4 weeks from any investigational (not Food and Drug Administration&#xD;
                  (FDA)-approved) agents&#xD;
&#xD;
               -  2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g.,&#xD;
                  erlotinib, hydroxychloroquine, etc.)&#xD;
&#xD;
                    -  Patients must have a Karnofsky performance status &gt;= 60% (i.e. the patient&#xD;
                       must be able to care for himself/herself with occasional help from others)&#xD;
&#xD;
                    -  Absolute neutrophil count &gt;= 1,500/microliter (mcL)&#xD;
&#xD;
                    -  Platelets &gt;= 100,000/mcL&#xD;
&#xD;
                    -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
                    -  Total bilirubin =&lt; institutional upper limit of normal&#xD;
&#xD;
                    -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase&#xD;
                       (SGOT))/ alanine aminotransferase (ALT) (serum glutamate pyruvate&#xD;
                       transaminase (SGPT)) =&lt; 4 x institutional upper limit of normal&#xD;
&#xD;
                    -  Creatinine =&lt; institutional upper limit of normal OR creatinine clearance &gt;=&#xD;
                       60 ml/min/1.73m^2 for patients with creatinine levels above institutional&#xD;
                       normal&#xD;
&#xD;
                    -  Activated partial thromboplastin time (APTT) or partial thromboplastin time&#xD;
                       (PTT) =&lt; 1.5 x institutional upper limit of normal&#xD;
&#xD;
                    -  Patients must be able to provide written informed consent&#xD;
&#xD;
                    -  Women of childbearing potential must have a negative serum pregnancy test&#xD;
                       prior to study start; women of childbearing potential and men must agree to&#xD;
                       use adequate contraception (hormonal or barrier method of birth control;&#xD;
                       abstinence) prior to study entry, for the duration of study participation,&#xD;
                       and through 30 days after the last dose of study drug; should a woman become&#xD;
                       pregnant or suspect she is pregnant while participating in this study, she&#xD;
                       should inform her treating physician immediately; men treated or enrolled on&#xD;
                       this protocol must also agree to use adequate contraception prior to the&#xD;
                       study, for the duration of study participation, and through 30 days after&#xD;
                       the last dose of study drug&#xD;
&#xD;
                    -  Patients must have no concurrent malignancy except curatively treated basal&#xD;
                       or squamous cell carcinoma of the skin or carcinoma in situ of the cervix,&#xD;
                       breast, or bladder; patients with prior malignancies must be disease-free&#xD;
                       for &gt;= five years&#xD;
&#xD;
                    -  Patients must be able to swallow tablets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Patients receiving any other investigational agents are ineligible&#xD;
&#xD;
               -  Patients must not have received prior anti- Vascular endothelial growth factor&#xD;
                  (VEGF) therapy including bevacizumab (i.e. patients must be bevacizumab naive)&#xD;
&#xD;
               -  Patients with a history of allergic reactions attributed to compounds of similar&#xD;
                  chemical or biologic composition to PT2385 are ineligible&#xD;
&#xD;
               -  Patients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for&#xD;
                  treatment on this protocol; patients may be on non-enzyme inducing anti-epileptic&#xD;
                  drugs or not be taking any anti-epileptic drugs; patients previously treated with&#xD;
                  EIAED may be enrolled if they have been off the EIAED for 10 days or more prior&#xD;
                  to the first dose of PT2385&#xD;
&#xD;
               -  Patients with a history of bleeding diathesis are ineligible&#xD;
&#xD;
               -  Patients who have not recovered to &lt; Common Terminology Criteria for Adverse&#xD;
                  Events (CTCAE) grade 2 toxicities related to prior therapy are ineligible&#xD;
&#xD;
               -  Patients with uncontrolled intercurrent illness including, but not limited to,&#xD;
                  ongoing or active infection, symptomatic congestive heart failure, clinically&#xD;
                  significant cardiac disease, unstable angina pectoris, cardiac arrhythmia, or&#xD;
                  psychiatric illness/social situations that would limit compliance with study&#xD;
                  requirements, are ineligible&#xD;
&#xD;
               -  Pregnant women are excluded from this study; breastfeeding should be discontinued&#xD;
                  if the mother is treated with PT2385&#xD;
&#xD;
               -  Human immunodeficiency virus (HIV)-positive patients on combination&#xD;
                  antiretroviral therapy are ineligible due to potential drug-drug interactions&#xD;
                  with PT2385&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy Strowd, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest /ABTC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abrams Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center at University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <results_first_submitted>August 31, 2020</results_first_submitted>
  <results_first_submitted_qc>August 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 21, 2020</results_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03216499/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment Sept 14, 2017 - March 9, 2018, all glioblastoma multiforme (GBM) patients</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (HIF-2 Alpha Inhibitor PT2385)</title>
          <description>Patients receive hypoxia inducible factor (HIF)-2 alpha inhibitor PT2385 per os (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Pharmacological Study&#xD;
Laboratory Biomarker Analysis&#xD;
Pharmacogenomic Study&#xD;
HIF-2 alpha Inhibitor PT2385: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacogenomic Study: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (HIF-2 Alpha Inhibitor PT2385)</title>
          <description>Patients receive HIF-2 alpha inhibitor PT2385 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Pharmacological Study&#xD;
Laboratory Biomarker Analysis&#xD;
Pharmacogenomic Study&#xD;
HIF-2alpha Inhibitor PT2385: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacogenomic Study: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" lower_limit="38.7" upper_limit="76.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MGMT Promoter Status</title>
          <description>O[6]-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme. In newly diagnosed glioblastomas, the presence of MGMT promoter methylation has been shown to be an independent favorable prognostic factor and a strong predictor of responsiveness to alkylating chemotherapy. The MGMT status reported is either methylated, not methylated or indeterminate.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Methylated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Methylated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Indeterminate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Extent of tumor resection</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Biopsy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subtotal resection</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Gross total resection</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status Score</title>
          <description>The Karnofsky Performance Status score is a standard way of measuring the ability of cancer patients to perform ordinary tasks with a score range from 0 to 100. A higher score means patient is better able to carry out daily activities: &quot;100 - Normal; no complaints, no evidence of disease; 90 - Able to carry on normal activity; minor signs or symptoms of disease, 80 - Normal activity with effort; some signs or symptoms of disease; 70 - Cares for self, unable to carry on normal activity or to do active work; 60 - Requires occasional assistance, but is able to care for most of personal needs&quot;</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80" lower_limit="70" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tumor Radiographic Response as Assessed by the RANO Criteria</title>
        <description>Tumor radiographic response assessed by Response Assessment in Neuro-Oncology (RANO) criteria.&#xD;
Complete Response (CR) = no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable or reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable or improved clinical status&#xD;
Partial Response (PR) = ≥50% change in size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status&#xD;
Stable Disease (SD) = &lt;50% reduction to &lt;25% increase size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status&#xD;
Progressive Disease (PD) = ≥25% increase size of T1-Gd+ disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status.</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (HIF-2 Alpha Inhibitor PT2385)</title>
            <description>Patients receive HIF-2 alpha inhibitor PT2385 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Pharmacological Study&#xD;
Laboratory Biomarker Analysis&#xD;
Pharmacogenomic Study&#xD;
HIF-2alpha Inhibitor PT2385: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacogenomic Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Radiographic Response as Assessed by the RANO Criteria</title>
          <description>Tumor radiographic response assessed by Response Assessment in Neuro-Oncology (RANO) criteria.&#xD;
Complete Response (CR) = no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable or reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable or improved clinical status&#xD;
Partial Response (PR) = ≥50% change in size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status&#xD;
Stable Disease (SD) = &lt;50% reduction to &lt;25% increase size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status&#xD;
Progressive Disease (PD) = ≥25% increase size of T1-Gd+ disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>complete response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>partial response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>stable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>progression</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS (in months) will be estimated using Kaplan-Meier method along with 95% confidence interval. Definition of PFS is date treatment started to the date of progression.</description>
        <time_frame>Assessed up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (HIF-2 Alpha Inhibitor PT2385)</title>
            <description>Patients receive HIF-2 alpha inhibitor PT2385 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Pharmacological Study&#xD;
Laboratory Biomarker Analysis&#xD;
Pharmacogenomic Study&#xD;
HIF-2alpha Inhibitor PT2385: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacogenomic Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS (in months) will be estimated using Kaplan-Meier method along with 95% confidence interval. Definition of PFS is date treatment started to the date of progression.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.6" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival (in months) will be estimated using Kaplan-Meier method along with 95% confidence interval.</description>
        <time_frame>From the date of treatment start to the date of death occurrence/or censored at the time of last known alive, assessed up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (HIF-2 Alpha Inhibitor PT2385)</title>
            <description>Patients receive HIF-2 alpha inhibitor PT2385 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Pharmacological Study&#xD;
Laboratory Biomarker Analysis&#xD;
Pharmacogenomic Study&#xD;
HIF-2alpha Inhibitor PT2385: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacogenomic Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival (in months) will be estimated using Kaplan-Meier method along with 95% confidence interval.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="4.9" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade 3 and Grade 4 Adverse Events</title>
        <description>Number of participants experiencing grade 3 and grade 4 adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (HIF-2 Alpha Inhibitor PT2385)</title>
            <description>Patients receive HIF-2 alpha inhibitor PT2385 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Pharmacological Study&#xD;
Laboratory Biomarker Analysis&#xD;
Pharmacogenomic Study&#xD;
HIF-2alpha Inhibitor PT2385: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacogenomic Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade 3 and Grade 4 Adverse Events</title>
          <description>Number of participants experiencing grade 3 and grade 4 adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>grade 3 anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>grade 3 Hyperglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>grade 3 hyponatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>grade 3 Hypoxia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>grade 4 Hypoxia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacokinetics (Cmin) for PT2385</title>
        <description>Minimum concentration (Cmin) on Day 15 of cycle 1.&#xD;
Cycle 1, Week 1, Day 1, Pre-dose 1: within 15 minutes prior to dose&#xD;
Cycle 1, Week 1, Day 1, 6 Hours Post-dose 1: 6 hours +/- 15 minutes post-dose&#xD;
Cycle 1, Week 3, Day 15, Pre-dose 1: within 30 minutes prior to dose</description>
        <time_frame>Day 15 cycle 1</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacokinetics for PT2385 Drug Exposure</title>
        <description>Drug exposure levels in 3 groups: Cmin &gt;1000ng/mL; Cmin: 300-1000 ng/mL and Cmin &lt;300ng/mL</description>
        <time_frame>Day 15 cycle 1</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Determine Association Between Baseline Tumor Acidity and PT2385 (Imaging)</title>
        <description>Baseline Tumor acidity was measured using pH-weighted amine chemical exchange saturation transfer (CEST) MRI contrast on the Magnetic Resonance Imaging R^2 = &quot;reversible transverse relaxation rate&quot; (and is proportional to oxygen extraction and thus hypoxia).&#xD;
MTR = MTRasym &quot;the asymmetry in the magnetization transfer ratio at 3ppm from water&quot; (and it is a surrogate of tumor acidity (MTR) pH quantitative measure of the acidity or basicity (pH) of aqueous or other liquid solutions. Lower pH values correspond to solutions which are more acidic in nature, while higher values correspond to solutions which are more basic or alkaline.&#xD;
Exp = exposure Acid = Acidity Perit Tiss = Peritumoral Tissue Enh Tum = Enhancing Tumor DurTx = Duration treatment</description>
        <time_frame>At baseline</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (HIF-2 Alpha Inhibitor PT2385)</title>
          <description>Patients receive HIF-2 alpha inhibitor PT2385 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Pharmacological Study&#xD;
Laboratory Biomarker Analysis&#xD;
Pharmacogenomic Study&#xD;
HIF-2alpha Inhibitor PT2385: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacogenomic Study: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 5.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE 5.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>aniema</sub_title>
                <counts group_id="E1" events="30" subjects_affected="11" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema Limbs</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>lymphocyte decrease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>platelet count decrease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>muscle weakness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roy Strowd, MD</name_or_title>
      <organization>Adult Brain Tumor Consortium (ABTC)</organization>
      <phone>410-955-8837</phone>
      <email>jfisher@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

